Skye Bioscience (SKYE) Cash from Operations (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Cash from Operations of 8557917.0 for Q1 2026, up 6.83% year-over-year from 8010621.73 in Q1 2025, and up 12.37% quarter-over-quarter from 9766487.0 in Q4 2025.
Skye Bioscience (SKYE) Cash from Operations (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Cash from Operations for 15 consecutive years, with 8557917.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 6.83% year-over-year to 8557917.0; the TTM figure through Mar 2026 stood at 42434966.0 (down 42.81% YoY), while the FY2025 annual figure was 43062529.0, down 70.63% from the prior year.
- Cash from Operations grew to 8557917.0 in Q1 2026 per SKYE's latest filing, from 9766487.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1991836.0 in Q2 2023 and bottomed at 13364375.0 in Q3 2025.
- Historically, Cash from Operations has averaged 6091422.12 across 5 years, with a median of 4871522.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 31.34% — and 2024, when it tumbled 256.13%.
- Skye Bioscience's Cash from Operations stood at 4871522.0 in 2022, then rose by 21.08% to 3844718.0 in 2023, then tumbled by 112.58% to 8173103.0 in 2024, then decreased by 19.5% to 9766487.0 in 2025, then rose by 12.37% to 8557917.0 in 2026.
- Business Quant data shows SKYE's Cash from Operations at 8557917.0 in Q1 2026, 9766487.0 in Q4 2025, and 13364375.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | -7.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.56 Mn |
| Mar 31, 2026 | -8.56 Mn |
| Dec 31, 2025 | -9.77 Mn |
| Dec 31, 2025 | -9.77 Mn |
| Sep 30, 2025 | -13.36 Mn |
| Sep 30, 2025 | -13.36 Mn |
| Jun 30, 2025 | -10.75 Mn |
| Jun 30, 2025 | -10.75 Mn |
| Mar 31, 2025 | -9.19 Mn |
| Mar 31, 2025 | -9.19 Mn |
| Dec 31, 2024 | -8.17 Mn |
| Dec 31, 2024 | -8.17 Mn |
| Sep 30, 2024 | -5.26 Mn |
| Sep 30, 2024 | -5.26 Mn |
| Jun 30, 2024 | -7.09 Mn |
| Jun 30, 2024 | -7.09 Mn |
| Mar 31, 2024 | -4.71 Mn |
| Mar 31, 2024 | -4.71 Mn |
| Dec 31, 2023 | -3.84 Mn |
| Dec 31, 2023 | -3.84 Mn |